title: Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.
abstract: OBJECTIVE
  It is well known that CPT-11 (irinotecan) is biotransformed to its active metabolite, SN-38, by carboxylesterase in the liver and other tissues. However, little is known about its pharmacokinetics (PK) when administered intraperitoneally. The aim of our study was to develop a population pharmacokinetic model for CPT-11 and SN-38 following the intraperitoneal (IP) administration of CPT-11.
  
  
  METHODS
  Pharmacokinetic data obtained from 16 gastric adenocarcinoma patients with peritoneal seeding were used. Administered doses ranged from 50 to 250 mg/m(2). To measure CPT-11 and SN-38 levels, we collected samples of peritoneal fluid, plasma and urine 0, 0.5, 1.5, 2, 3.5, 8, 12, 25.5, 49 and 56 h after IP infusion. Several multicompartmental pharmacokinetic models were tested for CPT-11 and SN-38 in the sampled peritoneal fluid, plasma and urine. NONMEM ver. 6 was used throughout the model-building process.
  
  
  RESULTS
  Peak concentrations were achieved earlier for peritoneal SN-38 than for plasma SN-38. The apparent metabolic clearance of peritoneal and plasma CPT-11 to peritoneal and plasma SN-38 accounted for 0.2 and 7.3% of the total clearance of peritoneal and plasma CPT-11, respectively. The typical values of steady-state volume of distribution (Vss) (46.6 L/m(2)), inter-compartment clearance (6.70 L/h/m(2)) and clearance (16.0 L/h/m(2)) for plasma CPT-11 were estimated in a two-compartment PK model.
  
  
  CONCLUSIONS
  Our results demonstrate that a small fraction of intraperitoneally administered CPT-11 was metabolized in situ to active SN-38 and that the Vss of plasma CPT-11 following IP administration in our patient cohort was lower than that estimated in previous reports following the intravenous administration of CPT-11.
authors.affiliation: Medical Science Research Center, Dongguk University, Seoul, Korea.
authors.forename: Byung-Jin
authors.initials: BJ
authors.lastname: Ahn
authors.forename: Moon Ki
authors.initials: MK
authors.lastname: Choi
authors.forename: Young Suk
authors.initials: YS
authors.lastname: Park
authors.forename: Jeeyun
authors.initials: J
authors.lastname: Lee
authors.forename: Se Hoon
authors.initials: SH
authors.lastname: Park
authors.forename: Joon Oh
authors.initials: JO
authors.lastname: Park
authors.forename: Ho Yeong
authors.initials: HY
authors.lastname: Lim
authors.forename: Won Ki
authors.initials: WK
authors.lastname: Kang
authors.forename: Jae-Wook
authors.initials: JW
authors.lastname: Ko
authors.forename: Dong-Seok
authors.initials: DS
authors.lastname: Yim
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D000077146:Irinotecan; D008297:Male; D008962:Models, Theoretical; D009366:Neoplasm Seeding; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin
references.citation: Biomed Chromatogr. 2003 Dec;17(8):493-9
references.pmid: 14648604
references.citation: Clin Cancer Res. 1998 Nov;4(11):2747-54
references.pmid: 9829738
references.citation: Jpn J Cancer Res. 1995 Jan;86(1):111-6
references.pmid: 7737902
references.citation: J Clin Oncol. 2002 Aug 1;20(15):3293-301
references.pmid: 12149304
references.citation: Clin Pharmacokinet. 1997 Oct;33(4):245-59
references.pmid: 9342501
references.citation: Cancer Chemother Pharmacol. 2011 Jan;67(1):5-11
references.pmid: 20213078
references.citation: Anticancer Res. 1999 Sep-Oct;19(5B):4187-91
references.pmid: 10628373
references.citation: Ann Oncol. 1995 Feb;6(2):141-51
references.pmid: 7786822
references.citation: Ther Drug Monit. 2005 Aug;27(4):536-8
references.pmid: 16044114
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Sep 25;795(1):25-34
references.pmid: 12957166
references.citation: Gan To Kagaku Ryoho. 2002 Nov;29(12):2188-90
references.pmid: 12484033
references.citation: J Med Chem. 1994 Jan 7;37(1):40-6
references.pmid: 8289200
references.citation: J Chromatogr B Biomed Sci Appl. 1999 Dec 24;736(1-2):175-84
references.pmid: 10676997
references.citation: Clin Chem. 2003 Nov;49(11):1900-8
references.pmid: 14578322
references.citation: Clin Pharmacol Ther. 2002 Dec;72(6):638-47
references.pmid: 12496745
references.citation: Cancer Chemother Pharmacol. 1998;42(2):165-70
references.pmid: 9654118
references.citation: AAPS J. 2011 Jun;13(2):143-51
references.pmid: 21302010
references.citation: Gan To Kagaku Ryoho. 2001 Oct;28(11):1505-7
references.pmid: 11707965
references.citation: Ann Oncol. 1995 Feb;6(2):133-40
references.pmid: 7786821
references.citation: Clin Cancer Res. 2001 Aug;7(8):2182-94
references.pmid: 11489791
references.citation: Drug Metab Dispos. 2000 Apr;28(4):423-33
references.pmid: 10725311